Selected articles
Articles for label Benešová Věra are displayed.. Show all articles
Treatment of metastatic colorectal cancer in a 44‑year‑old woman with internal comorbidities – a case report
03/2021 MUDr. Věra Benešová
In this case report, I describe the course of treatment of metastatic colorectal cancer in a 44-year-old woman with type 1 diabetes mellitus with insulin therapy and hypertension. The decision on the treatment sequence respected the current recommendations for the treatment of metastatic colorectal cancer, namely: examination in a multidisciplinary team, determination of the genetic type of the tumor, placement of the tumor and the overall lineage of the patient. Because the tumor was KRAS, NRAS wild-type, multiple liver lesions have been found in both lobes and it was left-sided cancer, systemic chemotherapy FOLFOX6 in combination with an epidermal growth factor receptor inhibitor, panitumumab (Vectibix inj.), has been chosen.
ENTIRE ARTICLE
In this case report, I describe the course of treatment of metastatic colorectal cancer in a 44-year-old woman with type 1 diabetes mellitus with insulin therapy and hypertension. The decision on the treatment sequence respected the current recommendations for the treatment of metastatic colorectal cancer, namely: examination in a multidisciplinary team, determination of the genetic type of the tumor, placement of the tumor and the overall lineage of the patient. Because the tumor was KRAS, NRAS wild-type, multiple liver lesions have been found in both lobes and it was left-sided cancer, systemic chemotherapy FOLFOX6 in combination with an epidermal growth factor receptor inhibitor, panitumumab (Vectibix inj.), has been chosen.
Treatment of metastatic hormone‑dependent breast cancer with a combination of palbociclib and letrozole – case report
06/2020 MUDr. Věra Benešová
The antitumor effect of cyclin-dependent kinase 4/6 (CDK4 / 6) inhibitors in combination with hormonal therapy significantly prolongs progression-free survival with prolonged lifespan. The use of this combination therapy in routine clinical practice is fundamentally changing the treatment options of our patients.
ENTIRE ARTICLE
The antitumor effect of cyclin-dependent kinase 4/6 (CDK4 / 6) inhibitors in combination with hormonal therapy significantly prolongs progression-free survival with prolonged lifespan. The use of this combination therapy in routine clinical practice is fundamentally changing the treatment options of our patients.
Treatment of metastatic hormone dependent breast cancer with combination palbociclib and letrozol – case report
01/2020 Special Edition - MUDr. Věra Benešová
Anti-tumor effect of CDK4/6 inhibitors in combination with hormone therapy significantly prolong progression free survival with prolongation time of lifetime. The use of this combination therapy in routine clinical practice fundamentally changes the treatment options of our patients.
ENTIRE ARTICLE
Anti-tumor effect of CDK4/6 inhibitors in combination with hormone therapy significantly prolong progression free survival with prolongation time of lifetime. The use of this combination therapy in routine clinical practice fundamentally changes the treatment options of our patients.
The family of CDK4/6 inhibitors is growing
01/2018 MUDr. Věra Benešová
The breast carcinoma belongs among the most frequently occurred malignant female illnesses in our country. Implementation of the screening programme enables to detect carcinoma at the I. or at the II. clinical stage in spite of the fact that the diagnosis of patients at the metastatic stage takes place, metastasis occurs by already cured patients too. Approximately 70 % of patients affected by the breast carcinoma is hormonally positive. Application of hormonal treatment has currently been prioritized for its efficiency and favourable effect with low profile of toxicity. Exception are just the patients with visceral crisis. The issue of the hormonal treatment efficiency is the creation of resistance against it. One of the ways how to postpone creation of resistance against hormonal treatment and to improve its efficiency is to combine it with the inhibitors CDK4/6.
ENTIRE ARTICLE
The breast carcinoma belongs among the most frequently occurred malignant female illnesses in our country. Implementation of the screening programme enables to detect carcinoma at the I. or at the II. clinical stage in spite of the fact that the diagnosis of patients at the metastatic stage takes place, metastasis occurs by already cured patients too. Approximately 70 % of patients affected by the breast carcinoma is hormonally positive. Application of hormonal treatment has currently been prioritized for its efficiency and favourable effect with low profile of toxicity. Exception are just the patients with visceral crisis. The issue of the hormonal treatment efficiency is the creation of resistance against it. One of the ways how to postpone creation of resistance against hormonal treatment and to improve its efficiency is to combine it with the inhibitors CDK4/6.
New recommendations for testing of hereditary breast and ovarian carcinomas in routine clinical practice
04/2017 MUDr. Věra Benešová
The breast carcinoma belongs to the most frequently occurred malignant tumours by females. 90 up to 95 % of tumours emerge coincidentally. 5 up to 10% of tumours belong to hereditary tumours. The most common cause of the hereditary tumours is the mutation of the gene BRCA1/2. The following article deals with indication for the genetic test and medical care about those affected female patients.
ENTIRE ARTICLE
The breast carcinoma belongs to the most frequently occurred malignant tumours by females. 90 up to 95 % of tumours emerge coincidentally. 5 up to 10% of tumours belong to hereditary tumours. The most common cause of the hereditary tumours is the mutation of the gene BRCA1/2. The following article deals with indication for the genetic test and medical care about those affected female patients.